U.S. stock market midday update: Greenwich Lifesciences down 7.34%, clinical standards approved by the UK, analysts remain cautious

U.S. Stock Market Midday Update

Greenwich Lifesciences fell 7.34%. Based on recent key news:

1. On July 22, Greenwich Lifesciences announced that its FLAMINGO-01 trial received expanded approval in the UK. This move adds 5-10 potential trial sites in the UK, driving stock price volatility. Source: Reuters

2. On July 20, Greenwich Lifesciences provided a clinical update on FLAMINGO-01, stating that trial objectives have been met, with a projected cash burn rate of $2 million for the second quarter and a cash balance of $8.9 million. This financial information may affect investor confidence. Source: Reuters

3. On July 22, analyst ratings showed Greenwich Lifesciences with a hold rating, not included in the recommended buy list, which may affect market sentiment. Source: MarketBeat The biopharmaceutical industry has been volatile recently and requires attention.

Top Stocks by Industry Trading Volume

Arrowhead Pharmaceuticals rose 23.69%. Based on recent key news:

1. On July 22, Arrowhead Pharmaceuticals released positive research results for its new drug Plozasiran. The drug performed well in the SHASTA-3 and SHASTA-4 studies, with expectations to receive FDA approval by the end of 2026. This news drove the stock price up, with trading volume reaching $442 million, setting a new 52-week high. Source: Business Wire

2. On July 22, market sentiment turned bullish, with investors confident in Plozasiran's potential, believing it could become a drug with annual sales of $10 billion. The stock price surged as a result. Source: Business Wire

3. On July 22, Arrowhead Pharmaceuticals became a hot stock, with investors optimistic about its future performance, driving the stock price up. Source: Business Wire The biopharmaceutical industry has shown strong performance recently, with significant capital inflow.

AbbVie fell 0.58%. Based on recent key news:

1. On July 22, market analysis rated AbbVie as a moderate buy but did not include it in the top recommended stock list. Analysts believe five other stocks are more attractive, which may weaken investor confidence in AbbVie and affect its stock price.

2. On July 20, AbbVie relies on its main growth drivers Skyrizi and Rinvoq for strong financial performance while having several exciting pipeline candidates in the rapidly growing weight loss market. Nevertheless, analysts still consider AbbVie a strong buy choice, especially for dividend-seeking investors.

3. On July 21, AbbVie performed well in advertising spending, particularly with significant increases in television advertising for depression and bipolar disorder. This may reflect the company's aggressive marketing strategy, influencing investor expectations for its future growth The pharmaceutical industry has great growth potential, pay attention to policy changes.

Lakewood-Amedex rose 75.01%. Based on recent key news:

1. On July 22, Lakewood-Amedex released new resistance data for its Nu-3 drug. Nu-3 did not show induced resistance in continuous passage studies, supporting its membrane-disrupting mechanism and positioning it in the development of antimicrobial resistance. This news drove the stock price up.

2. On July 22, the company's statement mentioned that clinical trials may face risks, including failure to start or complete as expected, and product candidates may fail to demonstrate safety or efficacy. These risk factors may affect investor confidence.

3. On July 22, Lakewood-Amedex's press release emphasized the progress of its product development. Despite uncertainties, the market is optimistic about the potential of its antimicrobial drugs. The biotechnology industry has performed strongly recently, with significant capital inflows.

Stocks ranked among the top in industry market capitalization

Amgen rose 0.38%. Based on recent news,

1. On July 22, Amgen's annualized return over the past 15 years has exceeded the market by 1.3%, with an average annual return of 13.64%. This long-term performance has strengthened investor confidence, driving the stock price up. Source: Benzinga

2. On July 21, Amgen stated that a ruling from the U.S. Tax Court may be made this year. Previously, Amgen's stock price fell sharply due to failure to timely disclose tax risks. Investors are optimistic about the upcoming ruling, driving the stock price up. Source: Benzinga

3. On July 21, Amgen's main products Prolia and Repatha have performed well in the market, especially Repatha's broad application prospects in cardiovascular events and hyperlipidemia treatment, further boosting market confidence. Source: Benzinga The overall market performance is stable, with significant capital inflows